The official answer is no, regardless of brand (Ozempic, Wegovy), administration type (injections, pills), or active ingredient (semaglutide, tirzepatide)
This could be due to the structural characteristics of tirzepatide, which confer a longer half-life, reducing the impact of decreased drug clearance due to renal impairment, maintaining relatively constant blood concentrations, and ensuring sustained glycemic control
Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N
However, routine workplace or clinical drug tests rarely include peptide detection unless targeted
Mass-based testing supports identity review by comparing measured mass or fragmentation evidence with the expected peptide identity